Clemens Messerschmidt
Overview
Explore the profile of Clemens Messerschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foddis M, Blumenau S, Mueller S, Messerschmidt C, Rocca C, Pagnamenta A, et al.
Stroke
. 2025 Jan;
56(3):725-736.
PMID: 39866114
Background: Contrary to the common belief, the most commonly used laboratory C57BL/6J mouse inbred strain presents a distinctive genetic and phenotypic variability, and for several traits, the genotype-phenotype link remains...
2.
Dorel M, Klinger B, Mari T, Toedling J, Blanc E, Messerschmidt C, et al.
PLoS Comput Biol
. 2021 Nov;
17(11):e1009515.
PMID: 34735429
Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and...
3.
Messerschmidt C, Foddis M, Blumenau S, Muller S, Bentele K, Holtgrewe M, et al.
Sci Rep
. 2021 Mar;
11(1):6072.
PMID: 33727568
Recently, several genome-wide association studies identified PHACTR1 as key locus for five diverse vascular disorders: coronary artery disease, migraine, fibromuscular dysplasia, cervical artery dissection and hypertension. Although these represent significant...
4.
Quinn H, Vogel R, Popp O, Mertins P, Lan L, Messerschmidt C, et al.
Cancer Res
. 2021 Feb;
81(8):2116-2127.
PMID: 33574090
Targeting cancer stem cells (CSC) can serve as an effective approach toward limiting resistance to therapies. While basal-like (triple-negative) breast cancers encompass cells with CSC features, rational therapies remain poorly...
5.
Peitz C, Sprussel A, Linke R, Astrahantseff K, Grimaldi M, Schmelz K, et al.
J Mol Diagn
. 2020 Aug;
22(11):1309-1323.
PMID: 32858250
The detection and characterization of cell-free DNA (cfDNA) in peripheral blood from neuroblastoma patients may serve as a minimally invasive approach to liquid biopsy. Major challenges in the analysis of...
6.
Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, et al.
Int J Cancer
. 2020 May;
147(8):2293-2302.
PMID: 32468570
Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures,...
7.
Akpa C, Kleo K, Oker E, Tomaszewski N, Messerschmidt C, Lopez C, et al.
BMC Cancer
. 2020 May;
20(1):427.
PMID: 32408898
Background: Enhancer of zeste homolog 2 (EZH2) is considered an important driver of tumor development and progression by its histone modifying capabilities. Inhibition of EZH2 activity is thought to be...
8.
Obermayer B, Holtgrewe M, Nieminen M, Messerschmidt C, Beule D
PeerJ
. 2020 Mar;
8:e8607.
PMID: 32117635
Background: Single cell omics technologies present unique opportunities for biomedical and life sciences from lab to clinic, but the high dimensional nature of such data poses challenges for computational analysis...
9.
Lamping M, Benary M, Leyvraz S, Messerschmidt C, Blanc E, Kessler T, et al.
Eur J Cancer
. 2020 Jan;
127:41-51.
PMID: 31982633
Background: Reliable and reproducible interpretation of molecular aberrations constitutes a bottleneck of precision medicine. Evidence-based decision management systems may improve rational therapy recommendations. To cope with an increasing amount of...
10.
Seidel E, Walenda G, Messerschmidt C, Obermayer B, Peitzsch M, Wallace P, et al.
Endocr Connect
. 2020 Jan;
9(2):122-134.
PMID: 31910152
Mitotane is the only drug approved for the therapy of adrenocortical carcinoma (ACC). Its clinical use is limited by the occurrence of relapse during therapy. To investigate the underlying mechanisms...